Life Care News
A Hope Of True Information

Ultimovacs ASA: Annual Report 2022


Oslo, 24 March 2023: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of Ultimovacs ASA has approved the Annual Report and ESG Report for 2022.

Please find a PDF version of the annual report, as well as the report in European Single Electronic Format (ESEF), as attachments to this release. The Annual Report is also available at the company’s website:

This information is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.

For further information, please see or contact:

- Advertisement -

Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA


Phone: +47 480 96 355

Carlos de Sousa, CEO


Phone: +47 908 92507


Hans Vassgård Eid, CFO


Phone: +47 482 48632

Anne Worsøe, Head of Investor Relations & ESG


Phone: +47 90686815





Get real time updates directly on you device, subscribe now.